Lipase, Uric acid, HDL-Cholesterol, Enzymatic Creatinine assays 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Beckman Coulter 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2018-08-29
  • 사례 출판 날짜
    2018-08-29
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: beckman coulter lipase, uric acid, hdl-cholesterol, enzymatic creatinine assays medical device manufacturer, beckman coulter, has issued a medical device safety alert concerning its following devices: reference: lipase osr6x30; uric acid osr6x98; hdl-cholesterol osr6x87; enzymatic creatinine osr6x204 lot number: all lots the manufacturer informed that napqi (n-acetyl p benzoquinone imine), a metabolite of paracetamol, causes negative interference with enzymatic creatinine osr6x204, hdl- cholesterol osr6x87, lipase osr6x30 and uric acid osr6x98 assays, at levels present in the serum/plasma of overdose patients. napqi in toxic concentrations may potentially lead to erroneously low results for enzymatic creatinine, hdl cholesterol, lipase and uric acid. the risk to patient safety of this event has been determined as remote for enzymatic creatinine and highly unlikely for the remaining assays. paracetamol itself does not interfere with the assays. according to the manufacturer, no action is required by the laboratory. laboratories should be aware that there is a remote probability that napqi in toxic concentrations may potentially lead to erroneously low results for lipase, uric acid, hdl-cholesterol and enzymatic creatinine. the following statement will be added to the interfering substances section of the lipase, uric acid, hdl-cholesterol and enzymatic creatinine ifus (blosr6x30, blosr6x98, blosr6x87 and blosr6x204, respectively: "n-acetyl-p-benzoquillone imine (metabolite of paracetamol) will generate erroneously low results in samples for patients that have taken toxic doses of paracetamol. " according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 29 august 2018.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Beckman Coulter Lipase, Uric acid, HDL-Cholesterol, Enzymatic Creatinine assays
  • Manufacturer

Manufacturer